LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS MPNs MULTIPLE MYELOMA NTRK GENE FUSIONS SARCOMA SKIN CANCERSSKIN CANCERS THYROID CANCERS Choose Specialty March 27, 2020 ByBrad Kahl, MD Video Brad Kahl, MD, discusses the treatment options for patients with ind...
Most types of indolent NHLs are treatable and can respond many times to treatment, and that is why the survival prognosis is good for these patients. Indolent NHL patients who have some disease generally do not feel any different than patients who are in remission. This is important because ...
must be treated cautiously,” they wrote. “In the future, once there are better biomarkers and imaging techniques to predict which individuals with a diagnosis of lung cancer will have more or less aggressive disease, treatment options can be optimized, and a mass screening program can become ...
Objectives: Castration-resistant prostate cancer (CRPC) has retained a guarded prognosis, with historical survival estimates of 18 to 24 months. However, the landscape of available therapy has changed, and the emphasis has altered from supportive to active treatment. Few large series from real-world...
It also is rare for symptoms of ISM rarely pose an immediate threat or interfere with organ function. Indolent systemic mastocytosis treatment typically involves treating symptoms and reducing the risk of triggers. People with ISM often have low morbidity (chance of becoming ill) and a normal lif...
Aside from the stigma of a “cancer” diagnosis and the morbidity of aggressive treatment for PTC, patients and health care professionals have to cope with the rapidly increasing costs of care for patients with thyroid cancer, which were estimated to exceed $1.6 billion in 2013 in the United ...
treatment had no effect on the spleen size and weight in the CD19-Cre mice (not shown). After three weeks of treatment with mAbs against T and NK cells, T-cell depletion was very pronounced in the spleen and was almost complete in the blood (not shown). After CsA treatment, T cells...
The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.
Prognostic value of post-treatment 18F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy Objective:To clarify the prognostic value of post-treatment 18F-fluorodeoxyglucose(FDG) positron emission tomography(PET)/computed tomography(CT) in patien... ...
Data on treatment and outcomes were also collected. Overall survival (OS) was calculated from the time of diagnosis to the date of death from any cause or to the last follow-up date. Meanwhile, progression-free survival (PFS) was calculated from the time of diagnosis of smoldering- or ...